Core Viewpoint - 瑞慈医疗's acquisition of a residential unit in Shanghai is seen as a strong long-term investment opportunity due to the property's location in a key commercial and residential area of the city [1] Company Summary - 瑞慈医疗's wholly-owned subsidiary, Shanghai Ruici Ruibo Outpatient Department Co., Ltd., plans to purchase a residential unit with a total construction area of approximately 570.06 square meters for about RMB 199 million [1] - The board believes that the acquisition will provide a reasonable level of return for the company [1] Industry Summary - The property is located in the Xuhui District of Shanghai, which is recognized as a core commercial and living area, contributing to the city's status as an international hub for economy, finance, trade, logistics, and technological innovation [1] - Shanghai is characterized by robust economic advantages and significant development potential, creating a favorable investment environment [1] - The board is optimistic about the long-term capital appreciation potential of the property due to surrounding development projects and the overall growth of Shanghai [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 RICI HEALTHCARE HOLDINGS LIMITED （於開曼群島註冊成立的有限公司） （股份代號：1526） 須予披露交易 收購該物業 收購事項 董事會宣佈，於2025年11月4日（聯交所交易時段後），買方（本公司的全資附 屬公司）與賣方（獨立第三方）訂立上海市商品房預售合同，據此，買方同意 購買，且賣方同意出售該物業，代價為人民幣198,950,940元。 上市規則的涵義 由於收購事項涉及的最高適用百分比率（定義見上市規則）超過5%，但均低 於25%，故收購事項構成本公司的須予披露交易，因而須遵守上市規則第 十四章的相關通知及公告規定。 收購事項 董事會宣佈，於2025年11月4日（聯交所交易時段後），買方與賣方訂立上海市 商品房預售合同，據此，買方同意購買，且賣方同意出售該物業，代價為人民 幣198,950,940元。 – 1 – 上海市商品房預售合同 上海市商品房預售合同主要條款的概 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 瑞慈醫療服務控股有限公司（本公司）（於開曼群島注冊成立的有限公司） 呈交日期: 2025年11月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01526 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | USD | | 0.0001 USD | | 1,000,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 10,000,000,000 | USD | | 0.0001 USD | | 1,000,0 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 瑞慈醫療服務控股有限公司（本公司）（於開曼群島注冊成立的有限公司） 呈交日期: 2025年10月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01526 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | USD | 0.0001 | USD | | 1,000,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 10,000,000,000 | USD | | 0.0001 USD | | 1,000,00 ...

2025 INTERIM REPORT 中期報告 股份代號 Stock Code: 1526 於開曼群島註冊成立之有限公司 Incorporated in the Cayman Islands with limited liability 2025 目錄 | 釋義 | 2 | | --- | --- | | 公司資料 | 5 | | 管理層討論與分析 | 7 | | 補充資料 | 17 | | 中期財務資料審閱報告 | 28 | | 中期簡明綜合財務報表 | | | 中期簡明綜合資產負債表 | 29 | | 中期簡明綜合損益表 | 31 | | 中期簡明綜合其他全面收益表 | 32 | | 中期簡明綜合權益變動表 | 33 | | 中期簡明綜合現金流量表 | 34 | | 中期簡明綜合財務資料附註 | 35 | 2 5 7 釋義 於本中期報告，除文義另有所指外，下列詞彙具有以下涵義。 | 「審核委員會」 | 指 | 董事會審核委員會 | | --- | --- | --- | | 「董事會」 | 指 | 本公司董事會 | | 「英屬處女群島」 | 指 | 英屬處女群島 | | 「企業管治守則」 | 指 | 載 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 瑞慈醫療服務控股有限公司（本公司）（於開曼群島注冊成立的有限公司） 呈交日期: 2025年9月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01526 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | USD | | 0.0001 USD | | 1,000,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 10,000,000,000 | USD | | 0.0001 USD | | 1,000,000 ...

Core Insights - Ruici Medical Service Holdings Limited reported a revenue of 1.145 billion yuan and a gross profit of 408 million yuan for the period ending June 30, 2025 [1] - The company operates 86 health examination centers across 29 cities, with 76 centers already in operation [1] - The launch of the high-end health examination brand "Ruici Club" targets corporate executives and business elites, addressing the demand for efficient and high-quality health check-ups [1] - The ultra-high-end medical brand "Xingyuan Club" experienced significant growth in revenue and patient visits in the first half of 2025, reflecting the company's strategic focus on the high-end health examination market [1] - A strategic partnership was established between Nantong Ruici Hospital and Shanghai Oriental Hospital, enhancing Ruici Medical's service capabilities and brand influence in the Yangtze River Delta region [1] Operational Enhancements - The company is enhancing customer satisfaction through closed-loop management and initiatives like "Leading Action" and "Assistance Training" to improve medical quality and service experience [2] - Ruici Medical is integrating AI and digital technologies into the health examination process to boost operational efficiency and testing accuracy [2]

Core Viewpoint - 瑞慈医疗 reported a decline in revenue and profit for the six months ending June 30, 2025, compared to the same period in 2024, indicating potential challenges in its financial performance [1] Financial Performance - The company's revenue for the six months was RMB 1,144.8 million, a decrease of 7.0% from RMB 1,231.2 million in the same period of 2024 [1] - The profit attributable to the company's owners was RMB 55.9 million, down from RMB 85.0 million in 2024 [1] - Adjusted EBITDA for the period was RMB 386.6 million, a reduction of 5.4% from RMB 408.8 million in 2024 [1] Dividend Policy - The board of directors has decided not to declare any interim dividend for the reporting period [1]

Group 1 - The core viewpoint of the article is that 瑞慈医疗 (RuiCi Medical) reported a decline in both revenue and profit for the six months ending June 30, 2025, indicating challenges in its business operations [1] - The company achieved a revenue of 1.145 billion yuan, representing a year-on-year decrease of 7% [1] - The profit attributable to the company's owners was 55.941 million yuan, which is a year-on-year decrease of 34.18% [1] - The earnings per share were reported at 0.04 yuan [1] - The decline in revenue is primarily attributed to external competitive pressures affecting the comprehensive hospital business [1]

Core Viewpoint - 瑞慈医疗 reported a revenue of 1.145 billion yuan for the six months ending June 30, 2025, representing a year-on-year decrease of 7% [1] - The profit attributable to the company's owners was 55.941 million yuan, down 34.18% year-on-year, with earnings per share at 0.04 yuan [1] Revenue Performance - The decline in revenue is primarily attributed to the competitive pressure faced by the integrated hospital business, leading to a decrease in income [1]